Literature DB >> 3639088

Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.

C Cordova, F Violi, C Alessandri, D Ferro, M Saliola, F Balsano.   

Abstract

The activities of Hageman factor, high molecular weight kininogen (HMWK), and prekallikrein were studied in patients who had chronic active hepatitis and cirrhosis. Serum HMWK and prekallikrein activities were decreased in chronic active hepatitis and cirrhosis, but Hageman factor activity was low in cirrhosis only. The reduction of prekallikrein, HMWK, and Hageman factor was dependent on the degree of liver failure. Similar prekallikrein values were found in serum samples, activated or not, with an excess of Hageman factor and HMWK, which suggests that the decrease of prekallikrein in liver disease is not influenced by the simultaneous decrease of Hageman factor and HMWK.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3639088      PMCID： PMC500201          DOI： 10.1136/jcp.39.9.1003

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  10 in total

1.  Endotoxin, prekallikrein, complement and systemic vascular resistance. Sequential measurements in man.

Authors:  J A Robinson; M L Klondnycky; H S Loeb; M R Racic; R M Gunnar
Journal:  Am J Med       Date:  1975-07       Impact factor: 4.965

2.  Chromogenic substrate assay of plasma prekallikrein. With a note on its site of biosynthesis.

Authors:  H Stormorken; A Baklund; M Gallimore; S Ritland
Journal:  Haemostasis       Date:  1978

3.  Potentiation of the function of Hageman factor fragments by high molecular weight kininogen.

Authors:  C Y Liu; C F Scott; A Bagdasarian; J V Pierce; A P Kaplan; R W Colman
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

4.  Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. II. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein.

Authors:  R W Colman; L Mattler; S Sherry
Journal:  J Clin Invest       Date:  1969-01       Impact factor: 14.808

5.  Correlation between hepatic blood flow and coagulation indices in chronic active hepatitis and liver cirrhosis patients.

Authors:  F Violi; C Alessandri; M Saliola; V Caputo; M S Bonavita; F Balsano
Journal:  Haemostasis       Date:  1985

6.  Low doses of calcium-heparin in liver cirrhosis.

Authors:  C Cordova; F Violi; C Alessandri; A Musca; F Balsano
Journal:  Thromb Haemost       Date:  1985-08-30       Impact factor: 5.249

7.  Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein.

Authors:  C Kluft
Journal:  J Lab Clin Med       Date:  1978-01

8.  Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in health and disease in various animal plasmas.

Authors:  H Saito; G Goldsmith; R Waldmann
Journal:  Blood       Date:  1976-12       Impact factor: 22.113

9.  Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.

Authors:  C Cordova; A Musca; F Violi; C Alessandri; D Ferro; A Piromalli; F Balsano
Journal:  Haemostasis       Date:  1984

10.  Upper gastrointestinal haemorrhage in hepatic cirrhosis: causes and relation to hepatic failure and stress.

Authors:  D Franco; Y Durandy; A Deporte; H Bismuth
Journal:  Lancet       Date:  1977-01-29       Impact factor: 79.321
  10 in total
  2 in total

1.  Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis.

Authors:  F Violi; C Alessandri; D Ferro; M Saliola; C Cordova; A Musca; F Balsano
Journal:  J Clin Pathol       Date:  1989-12       Impact factor: 3.411

2.  Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury.

Authors:  Jürgen Borlak; Bijon Chatterji; Kishor B Londhe; Paul B Watkins
Journal:  Genome Med       Date:  2013-09-27       Impact factor: 11.117
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.